All In Biotech

Drug Trial Radar · NCT05284747

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 6,019 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

6,019

Actual

Start

Oct 26, 2022

Primary completion

May 29, 2027

Study completion May 29, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Colorado Prevention Center
First posted
Mar 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).

Conditions

  • Cardiovascular Disease
  • Myocardial Infarction
  • Stroke
  • Coronary Revascularization

Interventions

  • EvolocumabDrug

    Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.

  • Routine Lipid ManagementDrug

    Routine lipid management therapies will be administered at the discretion of the investigator per SoC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause deathTime frame: From Baseline to End of Study (Approximately 3.5 Years)

Locations

120 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Eastern Shore Research Institute

    Fairhope, Alabama

  • Heart Center Research LLC

    Huntsville, Alabama

  • Northern Arizona Healthcare Corporation Cardiovascular Institute

    Flagstaff, Arizona

  • Scottsdale Healthcare at Shea - HonorHealth

    Scottsdale, Arizona

  • Pima Heart and Vascular Clinical Research

    Tuscon, Arizona

  • John Muir Health and Cardiovascular Institute

    Concord, California

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California-Irvine

    Orange, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Hartford Hospital

    Hartford, Connecticut

  • Cardiology Associates of Fairfield County PC

    Stamford, Connecticut

  • Excel Medical Clinical Trials

    Boca Raton, Florida

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida

  • University of Florida at Gainesville

    Gainesville, Florida

  • University of Florida and Shands Hospital

    Jacksonville, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Cardiology Partners Clinical Research Institute

    Palm Beach Gardens, Florida

  • Baptist Health Care

    Pensacola, Florida

  • Ascension Sacred Heart

    Pensacola, Florida

  • Clearwater Cardiovascular Consultants

    Safety Harbor, Florida

  • Tampa Cardiovascular Interventions and Research

    Tampa, Florida

  • Clinical Site Partners Orlando dba Flourish Research

    Winter Park, Florida

  • Saint Lukes Boise Medical Center

    Boise, Idaho

  • Jesse Brown Veterans Affairs Medical Center

    Chicago, Illinois

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois

  • Ascension Saint Vincent Heart Center

    Indianapolis, Indiana

  • Reid Physician Associates

    Richmond, Indiana

  • University of Kansas Hospital

    Kansas City, Kansas

  • Midwest Heart and Vascular Specialists

    Overland Park, Kansas

  • University of Louisville Health - Jewish Hospital

    Louisville, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Healthy Heart Cardiology

    Grand Rapids, Michigan

  • Sparrow Clinical Research Institute

    Lansing, Michigan

  • McLaren Macomb Research Services

    Mount Clemens, Michigan

  • McLaren Northern Michigan Hospital

    Petoskey, Michigan

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.